IRIS UniCatt

Richeldi, Luca
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.602
AS - Asia 6.153
EU - Europa 5.210
SA - Sud America 1.818
AF - Africa 221
OC - Oceania 51
Continente sconosciuto - Info sul continente non disponibili 10
Totale 20.065
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.309
SG - Singapore 2.983
BR - Brasile 1.517
IT - Italia 1.339
CN - Cina 1.305
SE - Svezia 1.012
DE - Germania 526
PL - Polonia 449
VN - Vietnam 432
GB - Regno Unito 349
FR - Francia 326
IE - Irlanda 324
ID - Indonesia 265
IN - India 198
RU - Federazione Russa 193
HK - Hong Kong 188
FI - Finlandia 186
CA - Canada 152
AR - Argentina 105
BD - Bangladesh 101
MX - Messico 99
AT - Austria 94
KR - Corea 94
JP - Giappone 83
NL - Olanda 78
IQ - Iraq 70
TR - Turchia 63
BE - Belgio 57
UA - Ucraina 57
ZA - Sudafrica 51
SA - Arabia Saudita 50
IR - Iran 43
EC - Ecuador 42
PK - Pakistan 42
ES - Italia 41
AU - Australia 37
CO - Colombia 37
MA - Marocco 37
CZ - Repubblica Ceca 31
VE - Venezuela 31
CH - Svizzera 28
PY - Paraguay 28
JO - Giordania 26
AE - Emirati Arabi Uniti 25
CI - Costa d'Avorio 25
EG - Egitto 25
TW - Taiwan 25
LT - Lituania 23
PE - Perù 23
TN - Tunisia 20
KE - Kenya 19
UZ - Uzbekistan 18
MY - Malesia 17
IL - Israele 16
PH - Filippine 16
UY - Uruguay 16
NZ - Nuova Zelanda 14
PT - Portogallo 14
RO - Romania 14
AZ - Azerbaigian 11
GR - Grecia 10
KZ - Kazakistan 10
BO - Bolivia 9
CL - Cile 9
NP - Nepal 9
CR - Costa Rica 8
EU - Europa 8
OM - Oman 8
BG - Bulgaria 7
DZ - Algeria 7
KG - Kirghizistan 7
ET - Etiopia 6
LB - Libano 6
LK - Sri Lanka 6
NO - Norvegia 6
TH - Thailandia 6
TT - Trinidad e Tobago 6
BZ - Belize 5
DK - Danimarca 5
DO - Repubblica Dominicana 5
EE - Estonia 5
GE - Georgia 5
HN - Honduras 5
LV - Lettonia 5
MD - Moldavia 5
NG - Nigeria 5
PA - Panama 5
SD - Sudan 5
SN - Senegal 5
AL - Albania 4
AO - Angola 4
BH - Bahrain 4
GA - Gabon 4
HR - Croazia 4
HU - Ungheria 4
PS - Palestinian Territory 4
RS - Serbia 4
BY - Bielorussia 3
JM - Giamaica 3
KW - Kuwait 3
Totale 20.028
Salva come PNG Salva come JPEG
Città #
Singapore 1.306
Ashburn 759
Chandler 675
Warsaw 422
Beijing 383
Fairfield 332
Dublin 321
Rome 311
Milan 246
Jakarta 224
Hefei 206
New York 204
Wilmington 192
Los Angeles 176
Dallas 171
Hong Kong 166
Houston 163
Munich 158
Woodbridge 157
Boston 153
Princeton 148
Seattle 146
Ho Chi Minh City 141
The Dalles 140
San Mateo 136
São Paulo 136
Chicago 135
Moscow 115
Helsinki 112
Ann Arbor 105
Cambridge 95
Frankfurt am Main 90
Hanoi 90
Nuremberg 86
London 67
Kent 64
Boardman 63
Seoul 62
North Bergen 61
Tokyo 57
Rio de Janeiro 53
Brussels 47
Jacksonville 45
Santa Clara 45
Atlanta 43
Buffalo 43
Vienna 39
Brooklyn 38
Lappeenranta 38
Marseille 38
Bremen 37
Denver 36
Mexico City 35
Stockholm 35
Augusta 34
Council Bluffs 34
Toronto 31
Düsseldorf 30
Amsterdam 28
Belo Horizonte 28
Dearborn 28
Johannesburg 28
Poplar 28
Redwood City 28
Dong Ket 27
Hyderabad 27
Washington 27
Amman 26
Baghdad 26
Dhaka 26
Montreal 26
Phoenix 26
Abidjan 25
Kish 25
Nanjing 25
Turku 25
Chennai 24
Orem 24
Pune 24
Cattolica 23
Curitiba 23
Brasília 21
Fortaleza 21
Trieste 21
Bologna 20
Casalecchio di Reno 20
Guarulhos 20
San Diego 20
Ankara 19
Buenos Aires 19
Dammam 19
Goiânia 19
Norwalk 19
Shanghai 19
Hangzhou 18
Kunming 18
Nairobi 18
Campinas 17
Hải Dương 17
Manchester 17
Totale 10.434
Salva come PNG Salva come JPEG
Nome #
Post-COVID-19 global health strategies: the need for an interdisciplinary approach 496
Educational interventions alone and combined with port protector reduce the rate of central venous catheter infection and colonization in respiratory semi-intensive care unit. 419
Asthma in patients admitted to emergency department for COVID-19: prevalence and risk of hospitalization 249
Post-COVID-19 global health strategies: the need for an interdisciplinary approach 206
Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage 198
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19 196
Fatigue in Covid-19 survivors: The potential impact of a nutritional supplement on muscle strength and function 194
Subclinical interstitial lung abnormalities: Lumping and splitting revisited 193
Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis 181
Idiopathic Pulmonary Fibrosis: State of the Art for 2023 179
Demystifying fibrotic hypersensitivity pneumonitis diagnosis: it's all about shades of grey 178
Fatigue in Covid-19 survivors: The potential impact of a nutritional supplement on muscle strength and function 174
Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): Insights from the INPULSIS® trials 174
Balancing evidence and frontline experience in the early phases of the COVID-19 pandemic: current position of the Italian Society of Anti-infective Therapy (SITA) and the Italian Society of Pulmonology (SIP) 171
Retinal capillary involvement in early post-COVID-19 patients: a healthy controlled study 171
Assessment of neurological manifestations in hospitalized patients with COVID-19 170
A real-time integrated framework to support clinical decision making for covid-19 patients 157
Reply to Moodley and to Ravaglia et al 154
Gemelli decision tree Algorithm to Predict the need for home monitoring or hospitalization of confirmed and unconfirmed COVID-19 patients (GAP-Covid19): preliminary results from a retrospective cohort study 147
Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life 147
Residual respiratory impairment after COVID-19 pneumonia 146
Vaccines and Myocardial Injury in Patients Hospitalized for COVID-19 Infection: the CardioCOVID-Gemelli Study 145
COVID-19 atypical Parsonage-Turner syndrome: a case report 144
Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients 141
Lung ultrasonography for early management of patients with respiratory symptoms during COVID-19 pandemic 138
Malnutrition in COVID-19 survivors: prevalence and risk factors 137
Residual respiratory impairment after COVID-19 pneumonia 137
Malnutrition in COVID-19 survivors: prevalence and risk factors 136
Autophagy inhibition-mediated epithelial–mesenchymal transition augments local myofibroblast differentiation in pulmonary fibrosis 135
Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients 134
Sarilumab use in severe SARS-CoV-2 pneumonia 134
Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry 131
Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial 129
Psychological Distress After Covid-19 Recovery: Reciprocal Effects With Temperament and Emotional Dysregulation. An Exploratory Study of Patients Over 60 Years of Age Assessed in a Post-acute Care Service 128
Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: Pooled data from six clinical trials 127
Utility of a Molecular Classifier as a Complement to High-Resolution Computed Tomography to Identify Usual Interstitial Pneumonia 127
Mediastinal lymph node enlargement in idiopathic pulmonary fibrosis: Relationships with disease progression and pulmonary function trends 122
Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: Evidences from the Severe Asthma Network Italy (SANI) registry 119
Obstructive sleep apnea in sarcoidosis and impact of cpap treatment on fatigue 119
Disease progression across the spectrum of idiopathic pulmonary fibrosis: A multicentre study 118
Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis 116
Digital lung auscultation: Will early diagnosis of fibrotic interstitial lung disease become a reality? 115
The characterisation of interstitial lung disease multidisciplinary team meetings: A global study 114
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19 112
Agreement between chest ultrasonography and chest X-ray in patients who have undergone thoracic surgery: Preliminary results 112
Antibody-based therapies for idiopathic pulmonary fibrosis 112
Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial 106
Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI) 106
Challenges in COVID-19: is pulmonary thromboembolism related to overall severity? 105
Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline 105
Acute Respiratory Distress Syndrome and Lung Fibrosis Complicating Surgery in a Patient with Crohn's Disease 105
Severe asthma: One disease and multiple definitions 104
Accuracy and Predictors of Success of EUS-B-FNA in the Diagnosis of Pulmonary Malignant Lesions: A Prospective Multicenter Italian Study 104
Are newly launched pharmacotherapies efficacious in treating idiopathic pulmonary fibrosis? Or is there still more work to be done? 103
Challenges in COVID-19: is pulmonary thromboembolism related to overall severity? 103
Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposure to adults with COVID-19: Preliminary findings 103
Telemedicine-enabled, Hotel-based Management of Patients with COVID-19: A Single-Center Feasibility Study 102
Impact of chest imaging quality on the diagnosis of the usual interstitial pneumonia pattern: a hub and spoke study 101
Challenges in the diagnosis of idiopathic pulmonary fibrosis: the importance of a multidisciplinary approach 100
Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society 100
Molecular Testing in EBUS-TBNA Specimens of Lung Adenocarcinoma: A Study of Concordance Between Cell Block Method and Liquid-Based Cytology in Appraising Sample Cellularity and EGFR Mutations 99
Experimental autotaxin inhibitors for the treatment of idiopathic pulmonary fibrosis 98
Idiopathic pulmonary fibrosis 98
Progressive Fibrosing Interstitial Lung Disease A Proposed Integrated Algorithm for Management 98
Antibody-based therapies for idiopathic pulmonary fibrosis 96
A randomized trial of pamrevlumab in patients with COVID-19 pneumonia 95
Are newly launched pharmacotherapies efficacious in treating idiopathic pulmonary fibrosis? Or is there still more work to be done? 95
Case of a 33-Year-Old Woman With Hemoptysis and Migrant Nodular Cavitary Lesions 94
Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper 94
Idiopathic Pulmonary Fibrosis Is Associated with Common Genetic Variants and Limited Rare Variants 93
Observational, Multicenter Study on the Efficacy, Tolerability, and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis Older than 80 Years 93
Statin therapy and lung disorders 93
Current and Future Idiopathic Pulmonary Fibrosis Therapy 93
Home spirometry to assess efficacy of pirfenidone in progressive unclassifiable interstitial lung disease: better the devil you know than the devil you don't 93
BI 1015550: an investigational phosphodiesterase 4B (PDE4B) inhibitor for lung function decline in idiopathic pulmonary fibrosis (IPF) 92
COVID-19 Vaccine in Patients with Exacerbation of Idiopathic Pulmonary Fibrosis 91
New frontiers in ultrasonography of the mediastinum: Pediatric EBUS-TBNA 89
Treatment strategies for asthma: Reshaping the concept of asthma management 89
Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis 88
COVID-19 and interstitial lung disease: Keep them separate 87
Concordance and Prognostic Relevance of Different Definitions of Systemic Sclerosis Interstitial Lung Disease Progression 86
Fatigue in Covid-19 survivors: The potential impact of a nutritional supplement on muscle strength and function 86
Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial 86
Ultrasonography of the Mediastinum: Techniques, Current Practice, and Future Directions 85
Determinants and Evolution of Obstructive Sleep Apnea Syndrome After Myocardial Infarction 85
Advances with pharmacotherapy for the treatment of interstitial lung disease 85
Novel insights in fibrotic pulmonary sarcoidosis 84
Detection and Early Referral of Patients With Interstitial Lung Abnormalities: An Expert Survey Initiative 83
The management of Familial Pulmonary Fibrosis in different medical settings: Where does that leave us? An Italian nationwide survey 82
Phase 2B Study of Inhaled RVT-1601 for Chronic Cough in Idiopathic Pulmonary Fibrosis: A Multicenter, Randomized, Placebo-controlled Study (SCENIC Trial) 81
Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study 81
Multidisciplinary Evaluation of Interstitial Lung Diseases: New Opportunities Linked to Rheumatologist Involvement 80
Ultrasound-guided needle aspiration biopsy of isolated anterior mediastinal masses 79
Predictors of Stability/Improvement of Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis After One Year of Treatment With Nintedanib 79
COVALENCE STUDY: Immunogenicity and Reactogenicity of a COVID-19 mRNA Vaccine in an Open-Label Cohort of Long-Survivor Patients with Metastatic Lung Cancer 79
Reliability of crackles in fibrotic interstitial lung disease: a prospective, longitudinal study 79
Existing and emerging biomarkers for disease progression in idiopathic pulmonary fibrosis 79
Early diagnosis of idiopathic pulmonary fibrosis: Closer to the goal? 79
Evaluation of the lung microbiome as a therapeutic target in the management of idiopathic pulmonary fibrosis: role of antioxidant/antibiotic combination therapy 78
An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis: a look towards 2023 and beyond 78
Totale 12.431
Salva come PNG Salva come JPEG
Categoria #
all - tutte 101.173
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 101.173
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021939 0 0 0 0 0 116 256 199 88 133 72 75
2021/20221.506 141 75 29 155 56 48 30 237 61 68 339 267
2022/20232.924 315 302 274 430 270 355 136 179 310 147 132 74
2023/20242.037 69 436 91 100 102 211 136 75 90 149 234 344
2024/20254.633 121 97 362 202 306 208 220 229 751 411 923 803
2025/20267.075 1.672 551 971 1.706 2.025 150 0 0 0 0 0 0
Totale 20.421